Navigation Links
FDA Advisers Don't Back Epilepsy Drug Warnings

Experts do find 11 anti-seizure drugs heighten suicide risk, and they recommend medication guide for doctors

THURSDAY, July 10 (HealthDay News) -- Anti-seizure drugs can cause increased suicidal tendencies in patients, but not enough to warrant the government's strongest warning label on them, a U.S. health advisory panel concluded Thursday.

The 20-member panel voted unanimously, with one abstention, to back the findings on 11 antiepileptic drugs studied by the U.S. Food and Drug Administration.

In late January, the FDA announced it was considering a black-box warning after an agency review of 199 studies comparing the drugs, which are used by millions, to placebos. That review found that patients taking the drugs had about twice the risk of suicidal behavior compared with patients taking a placebo.

"We have concluded this was a real signal, and the signal applied to all drugs we studied," Dr. Russell Katz, director of the division of neurology products at the FDA's Center for Drug Evaluation and Research, told reporters at a late-afternoon teleconference Thursday.

"We propose that labels for all these antiepileptic drugs be changed to include a box warning, and patients should be given a medication guide describing these events with each prescription refill," he said.

On Thursday, the advisory panel appeared to agree with him -- up to a point. It voted in favor of sending a medication guide to doctors detailing the suicide risks.

But a majority of panel members voted against adding the black box warning, saying the studies didn't show a high-enough risk for suicidal behavior.

"The general view of the committee was concern that patients or physicians would not prescribe these drugs in certain circumstances where they should," Katz said. "The committee voted 14 'no, it should not be described in a box warning, although it should be described in the label somewhere.' There were four 'yes' votes and three abstensions."

Whether the FDA will follow the committee's recommendation against a black box warning will be a matter of discussion, Katz added.

"We take the committee's recommendations very seriously," he said.

The drugs reviewed by the FDA were: Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, Tegretol XR), Felbamate (marketed as Felbatol), Gabapentin (marketed as Neurontin), Lamotrigine (marketed as Lamictal), Levetiracetam (marketed as Keppra), Oxcarbazepine (marketed as Trileptal), Pregabalin (marketed as Lyrica), Tiagabine (marketed as Gabitril), Topiramate (marketed as Topamax), Valproate (marketed as Depakote, Depakote ER, Depakene, Depacon) and Zonisamide (marketed as Zonegran). Some of these drugs are also available as generics.

According to the FDA, antiepileptic drugs are used to treat epilepsy, bipolar disorder, migraine headaches and other conditions.

In January, the FDA was advising patients not to make any changes in their medication without talking to their doctor, said spokeswoman Sandy Walsh.

"Caregivers should pay close attention to changes in mood, behavior and actions," she said. "They should be aware of the development of these symptoms."

More information

For more on epilepsy, visit the Epilepsy Foundation.

SOURCES: July 10, 2008, teleconference with Russell Katz, M.D., director, Ddivision of neurology products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Md.; Sandy Walsh, spokeswoman, FDA

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Advisers Urge Ban on Cold Medicines for Young Children
2. U.S. Advisers OK Nasal Spray Flu Vaccine for Young Children
3. FDA Advisers Reject Over-the-Counter Statin
4. Growing Link Between Diabetes and Periodontal Disease Focus of National Gathering for Health Care Leaders
5. Treating your periodontal pockets may benefit your pocket book
6. Ortho Organizers(R) Announces the Launch of the Ancor Pro(TM) Orthodontic Anchorage System Hands-on Course
7. Survey confirms Americans prefer root canal treatment by endodontists
8. Most With High Blood Pressure Dont Follow Recommended Diet
9. Watch Your Mouth: Michigan Association of Endodontists Offers Four Part Series on Keeping Your Teeth Healthy
10. NYU dental researchers find evidence of periodontal disease leading to gestational diabetes
11. HPV, periodontitis work in tandem to increase risk of tongue cancer
Post Your Comments:
Related Image:
FDA Advisers Don't Back Epilepsy Drug Warnings
(Date:12/1/2015)... ... December 01, 2015 , ... On Tuesday 27 ... NASDAQ to educate the personnel on spinal decompression therapy and offer his professional ... nonsurgical procedure. The benefits come from creating negative intradiscal pressure which is conducive ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... rural West Tennessee to receive Gigabit Internet through a partnership this year with ... largest cities, Henderson is an attractive destination for entrepreneurs who want to build ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Florida Hospital Tampa is the ... of obesity in the state of Florida. , vBloc® Therapy is a vagal blocking therapy, ... 18 years with a body mass index (BMI) of at least 40 to 45 kg, ...
(Date:12/1/2015)... ... ... Califia Farms , one of the fastest growing natural beverage companies ... in Beverage World Magazine’s Global Packaging Design Awards, taking home the Gold in the ... a 2015 U.S.A. Taste Champion in the American Masters of Taste Championships for its ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... WellStar Health System has signed a definitive ... Tenet Healthcare,s five metro Atlanta ... move following the conclusion of the due diligence period. ... and patient safety programs that have resulted in increased ... --> --> With ...
(Date:12/1/2015)... 2015  Eyeon Therapeutics has received a Notice ... based on a charged hydrophilic polymer developed at ... product has been shown to be safe and ... Mark Mitchnick , MD, CEO states, "This second ... polymers in conjunction with a therapeutic agent.  Nanoparticles ...
(Date:12/1/2015)... , Dec. 1, 2015 Pharma Tech Outlook ... Top 10 Clinical Data Management Solution Providers - 2015 ... distinguished panel comprising CEOs, CIOs, VCs, analysts, and the ... illustrious list of top 10 clinical data management solution ... on pages 14 and 36 respectively). ...
Breaking Medicine Technology: